INS and type 1 diabetes mellitus: The second generation of basal insulin analogues—insulin degludec 100 units/mL (IDeg-100) and insulin glargine 300 units/mL (IGlar-300)—have even smoother pharmacokinetic/pharmacodynamic profiles than insulin glargine U100, are longer acting, and further lower glycemic variability, at least in patients with T1DM [9,10].